thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Regulatory Affairs questions

Question 20 of 20 Advanced Troubleshooting

FDA places your IND study on clinical hold. How do you respond?

Short answer

Stop the affected dosing as ordered, protect enrolled participants, and get the written hold letter that explains the basis. Fix each deficiency, then send a complete response addressing every item. FDA must reply in writing within 30 calendar days of receiving a complete response, and the study resumes only when FDA says so.

Why

Under 21 CFR 312.42, FDA can impose a clinical hold by phone or in writing, and the Division Director must provide a written explanation within 30 days. Grounds include unreasonable risk to participants, unqualified investigators, a misleading or incomplete investigator's brochure, or insufficient information to assess risk. A hold can apply to one or more studies under an IND.

During a hold on an ongoing study, no new participants may be dosed, and those already in it should come off the drug unless FDA specifically permits otherwise for their safety. The first actions are practical: tell sites, ask FDA at once about participants who may benefit from continuing, inform ethics committees, and check whether other regions' trials face the same issue. In the EU, a similar safety concern may require urgent safety measures and notification within 7 days under Article 54 of the Clinical Trials Regulation.

Then treat each hold item as a problem to solve. If FDA asks for more toxicology, run it. If it questions a dose, propose a revised one with data.

A response that leaves any item open is not complete and does not start the 30 day clock. Resumption needs FDA's notice, not just the passing of time.

How to work it through

  1. Read the hold notice and confirm the studies and activities it covers.
  2. Stop affected dosing and seek FDA's position on participants already on treatment.
  3. Notify ethics committees and assess impact on trials in other regions.
  4. List each deficiency and assign an owner and plan to resolve it.
  5. Submit a complete response that addresses every item with data.
  6. Track FDA's 30 day reply and resume only on written notice.

An example

After a grade 4 liver injury in cohort 3 of a dose escalation study, FDA places the study on clinical hold. The letter asks for a causality analysis, a liver monitoring plan and a revised maximum dose. The sponsor stops dosing the same day, asks FDA to let 4 participants with tumor responses continue at the cohort 2 dose under weekly liver tests, which FDA permits, and informs ethics committees and an EU competent authority.

Seven weeks later it submits a complete response with a hepatology review and a dose cap. FDA lifts the hold on day 26 after receipt.

Where the answer stops holding

Hold timing depends on the quality of the response, and new data during the hold can reopen questions. Which participants may continue treatment depends on FDA's specific permission, not the sponsor's own judgment. Parallel trials in other regions are governed by other rules and may need separate actions.

A strong answer covers

  • Stop affected activities and protect participants
  • Written basis within 30 days
  • Complete response addressing every item
  • FDA reply within 30 calendar days of a complete response
  • EU urgent safety measure parallel

Common mistakes

  • Resuming dosing after 30 days without FDA's written notice.
  • Sending a partial response and expecting the clock to start.
  • Forgetting to inform ethics committees and other regulators.